Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CAR-Lenti-ALLO
- Development stage
- Phase 1
- Lead developer
- Ospedale Pediatrico Bambino Gesù
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-CAR-Lenti-ALLO is an allogeneic, donor-derived chimeric antigen receptor (CAR) T cell therapy targeting the CD19 antigen on B cells. It is manufactured by transducing donor T cells with a lentiviral vector encoding a second-generation CAR construct that includes an anti-CD19 single-chain variable fragment (scFv), a 4-1BB costimulatory domain, and a CD3ζ signaling domain. This therapy is designed for patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), particularly those who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or are ineligible for autologous CAR-T products due to profound lymphopenia or rapidly progressing disease. In clinical studies, it has demonstrated efficacy in inducing complete remission with minimal residual disease negativity and has shown a manageable safety profile comparable to autologous CAR-T therapies[1].
- Other names
- CD19-CAR-Lenti_ALLO
02
Targets
Beyond the preview
Go deeper on CD19-CAR-Lenti-ALLO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CAR-Lenti-ALLO.